Drug Profile
MAGE A3/A6 TCR
Alternative Names: anti-MAGE A3/A6 TCRLatest Information Update: 16 Oct 2018
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA)
- Developer Kite Pharma
- Class Cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Oct 2018 No recent reports on development identified - Phase II for Soild tumours in USA (Parenteral)
- 03 Oct 2017 Kite Pharma has been acquired by Gilead Sciences
- 29 Feb 2016 Kite Pharma plans to file an IND application with the US FDA for a TCR product candidate that targets a MAGE antigen expressed on Solid tumours (Kite Pharma 8-K; February 2016)